How i treat... a patient presenting with mycosis fungoides;Comment je traite... un patient atteint de mycosis fongoïde

Revue Medicale de Liege

Volumn 61, Issue 11, 2006, Pages 740-746

  Pierard Franchimont C ^a   Pierard G E ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Lymphoma; Mycosis fungoides; Sezary syndrome

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BEXAROTENE; BLOOD CLOTTING FACTOR 13A; CARMUSTINE; CHLORMETHINE; CORTICOSTEROID; DENILEUKIN DIFTITOX; ETRETIN; METHOTREXATE;

CLINICAL FEATURE; CLINICAL STUDY; DIAGNOSTIC PROCEDURE; ERYTHEMA; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MYCOSIS FUNGOIDES; PHOTOTHERAPY; PROGNOSIS; PUVA; RADIODENSITOMETRY; REVIEW; SKIN LYMPHOMA; STAGING; SURGICAL TECHNIQUE; TREATMENT INDICATION; CANCER STAGING; SKIN TUMOR;

HUMANS; MYCOSIS FUNGOIDES; NEOPLASM STAGING; PROGNOSIS; SKIN NEOPLASMS;

EID: 39049188863     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Willemze R, Jaffe ES, Burg G, et al. - WHO-EORTC classification for cutaneous lymphomas. Blood, 2005, 105, 3768-3785.
2. Nikkeis AF, Quatresooz P, Delvenne P, et al. - Mycosis fungoides progression and chronic solvent exposure. Dermatology, 2004, 208, 171-172.
3. Grob JJ. - Epidémiologie du mycosis fongoïde. Ann Dermatol Venereol, 2005, 132, S11-S12.
4. Willemze R, Kerl H, Sterry W, et al. - EORTC classification for primary cutaneous lymphomas : a proposal from the cutaneous study group of the european organization for research and treatment of cancer. Blood, 1997, 90, 354-371.
5. Zackhei H, Amin S, Kashasni-Sabat M, McMillan A. - Prognosis in cutaneous T-cell lymphoma by skin stage : long-term survival in 489 patients. J Am Acad Dermatol, 1999, 40, 418-425.
6. Van Doom R, Van Haselen CW, Van Voorst PC, et al. - Mycosis fongoides : disease evolution and prognosis of 309 Dutch patients. Arch Dermatol, 2000, 136, 504-510.
7. Kim YH, Liu HL, Mraz-Gernhard S, et al. - Long-term outcome of 525 patients with mycosis fongoides and Sezary syndrome : clinical pronostic factors and risk for disease progression. Arch Dermatol, 2003, 139, 857-866.
8. Piérard GE, Piérard-Franchimont C, Hermanns-Lê T, et al. - Factor XIIIa positive dendritic cells in mycosis fongoides. Cancer J, 1992, 5, 226-229.
9. Fivenson DP, Nickoloff BJ. - Distinctive dendritic cell subsets expressing factor XIIIa, CD1a, CD1b and CD1c in mycosis fungoides and psoriasis. J Cutan Pathol , 1995, 22, 223-228.
10. Piérard GE, Franchimont C, Le T, et al. - Proliferation rate of cutaneous T cell lymphomas in the skin. Relationship with histological pattern and cytology. In : Lymphoproliferative diseases of the skin, Goos M, Christophers E (eds) Springer Verlag, Berlin, 1982, 65-70.
11. Piérard GE, Piérard-Franchimont C. - Patt ern of distribution and intensity of blastogenesis as clues for distinguishing pseudolymphomas from lymphomas. Br J Dermatol, 1983, 109, 253-259.
12. Cordel N, Lenormand B, Courville P, et al. - Usefulness of cutaneous T cell clonality analysis for the diagnosis of cutaneous T cell lymphoma in patients with erythroderma. Arch Pathol Lab Med, 2005, 129, 372-376.
13. Whittaker SJ, Marsden JR, Spittle M, Russell Jones R. - Joint British association of dermatologists and UK cutaneous lymphoma group guidelines for the management of primary cutaneous T cell lymphomas. Br J Dermatol, 2003, 149, 1095-1107.
14. de Quatrebarbes J, Esteve F, Bagot M, et al. - Treatment of early stage mycosis fongoides with twice-daily applications of mechlorethamine and topical corticosteroids : a prospective study. Arch Dermatol, 2005, 141, 1117-1120.
15. Jones GW, Kacinski BM, Wilson LD, et al. - Total skin electron radiation in the management of mycosis fongoides : concensus of the European Organisation of Research and Treatment of Cancer (EORTC) cutaneous lymphoma project group. J Am Acad Dermatol, 2002, 47, 364-370.
16. Duvic M, Martin AG, Kim Y, et al. - Worldwide bexarotene study group. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T cell lymphoma. Arch Dermatol, 2001, 137, 581-593.
17. Duvic M, Hymes K, Heald P, et al. - Bexarotene worldwide study group. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T cell lymphoma : multinational phase II-III trial results. J Clin Oncol, 2001, 19, 2456-2471.
18. McGinnis KS, Shapiro M, Vittorio CC, et al. - Psoralen plus long-wave UVA (PUVA) and bexarotene therapy : an effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T cell lymphoma. Arch Dermatol, 2003, 139, 881-775.
19. McGinnis KS, Junkins-Hopkins JM, Crawford G, et al. - Low-dose oral bexarotene in combination with low-dose intereferon alfa in the treatment of cutaneous T-cell lymphoma : clinical synergism and possible immunologic mechanisms. J Am Acad Dermatol, 2004, 50, 375-379.
20. Dreno B. - Interferon et lymphome cutané T épidermotrope. Ann Dermatol Venereol, 2005, 132, S37-S30.
21. Apisarnthanarax N, Talpur R, Duvic M. - Treatment of cutaneous T cell lymphomas. Current status and future directions. Am J Clin Dermatol, 2002, 3, 193-215.
22. Dereure O. - Traitements systémiques des lymphomes cutanés T épidermotropes (hors interferon et photophérèse). Ann Dermatol Venereol, 2005, 132, S31-S36.
23. Abou-Samra T, Viraben R, Dincan M. - Thérapeutiques immunomodulatrices innovantes en cours d'évaluation. Ann Dermatol Venereol, 2005, 132, S39-S41.